A clinical research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), and international genetic researchers led a global research study using multi-omics analysis and ...

A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...

Immune cell populations of people with post-vaccination syndrome had lower levels of effector CD4 T cells and higher levels ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

The drug fenfluramine has been recommended by the National Institute for Health and Care Excellence (NICE) for children with ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...

NICE has approved another epilepsy treatment for Lennox–Gastaut syndrome. Fenfluramine can be used as an add-on to other ...

The drug is the first non-cannabinoid option for patients with LGS and an alternative to Jazz Pharma's Epidyolex (cannabidiol ...

Starting today, the National Institute for Health and Care Excellence (NICE) has recommended the funding of fenfluramine for NHS patients in England. This new drug is specifically approved for ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.